Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol L: Sapanisertib in mTOR-mutated Tumors
NCT06385496Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in lymphoma, malignant solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Mar 2017; status: active, not recruiting.
02
Drugs
sapanisertib
03
Conditions
lymphomamalignant solid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06385496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385496.